arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

CRESCENT BIOPHARMA, INC.

CBIO

$14.17 ▼ -2.30 (-13.96%) at close

15 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

CRESCENT BIOPHARMA, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -76.2% ↗

FCF / Share None

Trailing P/E —

Price / Book 1.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$10.84M

↑ +108340.0% —

Net Income Profit after all expenses

$-153.94M

↓ -306.4% —

Operating Margin Operating profit as % of sales

-63.7%

↑ +14.1% —

FCF / Share Free cash flow per share

$-48.25

↑ +12.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Revenue Growth YoY (%)	—	—	-86.7% Weak → Weak Stable Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1183%)	-93.5% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1269%)	-88.6% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1207%)	—	—	—	—	-99.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1349%)	33.6% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+320%)	276.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3355%)	-73.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1023%)	—	—
EPS Growth YoY (%)	—	-1.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	34.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	27.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-9.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	93.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—
Net Income Growth YoY (%)	-306.4% Weak ↓ Weak Declining Year-over-year change in net income	-2.7% Weak ↓ Weak Declining Year-over-year change in net income	21.0% Good ↑ Good Improving Year-over-year change in net income	26.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-24.3% Weak ↓ Weak Declining Year-over-year change in net income	11.9% Fair ↑ Fair Improving Year-over-year change in net income	-19.9% Weak ↑ Weak Improving Year-over-year change in net income	-45.0% Weak ↑ Weak Improving Year-over-year change in net income	-4.6% Weak ↑ Weak Improving Year-over-year change in net income	-149.1% Weak ↓ Weak Declining Year-over-year change in net income	-14.8% Weak Weak Year-over-year change in net income	-4.9% Weak Weak Year-over-year change in net income	N/M	—	—
FCF Growth YoY (%)	—	12.4% Fair ↑ Fair Improving Year-over-year change in free cash flow	37.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	20.7% Good Good Year-over-year change in free cash flow	-30.0% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	424.9% Excellent Excellent Compound annual revenue growth over 3 years	—	-90.1% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—	-83.3% Weak Weak Compound annual revenue growth over 3 years	9.6% Fair Fair Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	1.3% Caution Caution Compound annual revenue growth over 5 years	—	—	—	128.8% Excellent Excellent Compound annual revenue growth over 5 years	-12.7% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	-63.7% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-525%)	-74.1% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-594%)	-265.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1871%)	23.8% Good Good Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+59%)	—
Effective Tax Rate (%) (%)	-1.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	-63.6% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-630%)	-74.0% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-717%)	-265.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2314%)	24.0% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+100%)	—
FCF Margin (%) (%)	—	—	—	—	—	-386.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.47x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Return on Invested Capital (%)	-76.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-595.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-80.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-87.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-61.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-19.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-71.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-25.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-17.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-288.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	22.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-63.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-361.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-86.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-91.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-67.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-24.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-75.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-200.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-75.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-606%)	—	-96.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-740%)	-108.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-825%)	-77.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-618%)	-39.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-365%)	-37.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-350%)	-23.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-257%)	-27.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-285%)	-90.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-701%)	-31.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-310%)	-21.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-246%)	—	29.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+95%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Net Debt (USD)	$-213.19M	$-10.72M	$-41.79M	$-47.87M	$-90.25M	$-137.04M	$-158.20M	$-209.92M	$-123.92M	$-40.04M	$-46.80M	$-55.20M	$-2.31M	$-17.37M	$-28.17M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Revenue per Share (USD)	—	—	$0.02	$0.14	$2.25	$22.23	—	—	—	—	—	$81.44	$333.79	$1.64K	—
Basic EPS, GAAP (USD)	—	$-59.00	$-58.00	$-89.00	$-123.00	$-112.00	—	—	—	—	—	$-60.00	$-887.00	$393.00	—
Free Cash Flow per Share (USD)	—	$-48.25	$-55.10	$-88.60	$-111.76	$-85.98	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$7.37	$8.24	$59.66	$78.95	$155.99	$261.58	$354.75	$476.04	$348.38	$151.83	$212.45	$268.24	$203.80	$1.35K	—
Tangible Book Value per Share (USD)	$7.37	$8.24	$59.66	$78.95	$155.99	$261.58	$354.75	$476.04	$348.38	$151.83	$212.45	$268.24	$203.80	$1.35K	—
Basic Weighted Avg Shares (shares)	—	644,772	633,425	525,312	514,532	457,211	—	—	—	—	—	184,523	11,962	9,296	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Working Capital (USD)	$200.58M	$5.31M	$36.96M	$41.83M	$78.96M	$125.84M	$151.58M	$203.51M	$119.04M	$34.19M	$39.50M	$49.65M	$2.60M	—	—
Total Equity (USD)	$203.01M	$5.31M	$38.41M	$42.93M	$81.60M	$128.22M	$154.20M	$205.46M	$119.70M	$35.30M	$40.47M	$50.80M	$2.91M	$12.53M	$8.46M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Sales/Revenue/Turnover (USD)	$10.84M	—	$10.00K	$75.00K	$1.16M	$10.16M	—	—	—	$18.50K	$20.07M	$15.03M	$3.99M	$15.26M	—
Depreciation Expense (USD)	$84.00K	$35.17K	$153.30K	$207.15K	$264.60K	$270.75K	$279.23K	$275.12K	$263.54K	$190.54K	$191.48K	$158.71K	$133.05K	$99.92K	—
Net Income, GAAP (USD)	$-153.94M	$-37.88M	$-36.90M	$-46.69M	$-63.43M	$-51.03M	$-57.89M	$-48.27M	$-33.28M	$-31.81M	$-12.77M	$-11.12M	$-10.61M	$3.66M	—
Operating Cash Flow (USD)	$-71.53M	$-31.10M	$-34.88M	$-46.46M	$-57.49M	$-39.24M	$-51.98M	$-43.33M	$-29.77M	$-29.73M	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 56 quarters

CRESCENT BIOPHARMA, INC.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CBIO with peers